Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.45 |
| ▸ | PRKDC | P78527 | 10/20 | 0.45 |
| ▸ | MTOR | P42345 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836721 | 1.00 | HPD (0.48) | HPDPIK3CAPRKDCMTORMAPT | |
| SCHEMBL5836712 | 0.78 | HPD (0.50) | HPDPIK3CAPRKDCMTORMAPT | |
| SCHEMBL6208794 | 0.73 | HPD (0.56) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL5838094 | 0.72 | PRKDC (0.41) | HPDPIK3CAPRKDCMTORMAPT | |
| SCHEMBL5838037 | 0.71 | HPD (0.48) | HPDPIK3CAPRKDCMTORMAPT | |
| SCHEMBL5836181 | 0.70 | HPD (0.53) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL2511811 | 0.70 | CES2 (0.52) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2511812 | 0.70 | CES2 (0.52) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5836096 | 0.69 | HPD (0.52) | HPDPIK3CAPRKDCMTORHSD11B1 | |
| SCHEMBL2510908 | 0.68 | SMN1; SMN2 (0.53) | MAPTPOLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056918-B2 | Benzimidazole anti-inflammatory compounds | PFIZER, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1370557-B1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | MAPK1, JAK1, CNKSR1 | HPD 4598/4885PIK3CA 1672/4885PRKDC 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.